Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 12/20 | 0.66 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 2/20 | 0.49 |
| ▸ | GLP1R | P43220 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17481432 | 0.99 | NOD1 (0.63) | NOD1SLC6A5EPHX2FAAHGLP1R | |
| SCHEMBL29664188 | 0.97 | NOD1 (0.71) | NOD1SLC6A5EPHX2FAAHGLP1R | |
| SCHEMBL28719145 | 0.97 | NOD1 (0.71) | NOD1SLC6A5EPHX2FAAHGLP1R | |
| SCHEMBL23193930 | 0.93 | NOD1 (0.61) | NOD1SLC6A5EPHX2FAAHGLP1R | |
| SCHEMBL17746988 | 0.92 | NOD1 (0.65) | NOD1SLC6A5EPHX2FAAHMEN1 | |
| SCHEMBL17746989 | 0.92 | NOD1 (0.65) | NOD1SLC6A5EPHX2FAAHMEN1 | |
| SCHEMBL29335571 | 0.90 | NOD1 (0.50) | NOD1SLC6A5 | |
| SCHEMBL29072117 | 0.89 | NOD1 (0.48) | NOD1SLC6A5EPHX2 | |
| SCHEMBL24630046 | 0.89 | NOD1 (0.48) | NOD1SLC6A5EPHX2 | |
| SCHEMBL29072118 | 0.89 | NOD1 (0.48) | NOD1SLC6A5EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180207276-A1 | MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH | 2018-07-26 | — | — | US | disclosed |
| WO-2016149501-A2 | MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2016-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207276-A1 | MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF | HDGF, ELANE, CD47 | NOD1 2428/4885SLC6A5 4772/4885EPHX2 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.